On the public citation graph

Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

0 signed · 451 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamadermatol.2014.2233openalex-snapshot
Drug-Associated Dermatomyositis Following Ipilimumab Therapy
inferredcites →https://doi.org/10.1001/jamaoncol.2015.4368openalex-snapshot
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
inferredcites →https://doi.org/10.1002/art.27549openalex-snapshot
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies
inferredcites →https://doi.org/10.1002/art.33379openalex-snapshot
Usefulness of anti‐p155 autoantibody for diagnosing cancer‐associated dermatomyositis: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1002/art.38093openalex-snapshot
Most Patients With Cancer‐Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP‐2 or Transcription Intermediary Factor 1γ
inferredcites →https://doi.org/10.1002/art.38282openalex-snapshot
Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4
inferredcites →https://doi.org/10.1002/art.39022openalex-snapshot
Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer‐Associated Scleroderma
inferredcites →https://doi.org/10.1002/art.39406openalex-snapshot
Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment
inferredcites →https://doi.org/10.1007/s00262-014-1607-yopenalex-snapshot
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
inferredcites →https://doi.org/10.1007/s10637-014-0092-7openalex-snapshot
Kidney injuries related to ipilimumab
inferredcites →https://doi.org/10.1016/j.ccell.2015.03.001openalex-snapshot
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
inferredcites →https://doi.org/10.1016/j.crohns.2014.08.002openalex-snapshot
Ipilimumab in a patient with known Crohn's disease: To give or not to give?
inferredcites →https://doi.org/10.1016/j.kint.2016.04.008openalex-snapshot
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
inferredcites →https://doi.org/10.1016/s1470-2045(15)70076-8openalex-snapshot
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1017/s0317167100007939openalex-snapshot
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
inferredcites →https://doi.org/10.1038/nature13904openalex-snapshot
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
inferredcites →https://doi.org/10.1038/nrrheum.2016.131openalex-snapshot
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
inferredcites →https://doi.org/10.1056/nejmc0904283openalex-snapshot
Anti-CTLA4 Antibody–Induced Lupus Nephritis
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1104621openalex-snapshot
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1411087openalex-snapshot
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1097/cco.0000000000000292openalex-snapshot
Checkpoint inhibitors and gastrointestinal immune-related adverse events
inferredcites →https://doi.org/10.1097/cco.0000000000000293openalex-snapshot
Endocrinological side-effects of immune checkpoint inhibitors
inferredcites →https://doi.org/10.1097/cji.0000000000000060openalex-snapshot
Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
inferredcites →https://doi.org/10.1097/iop.0000000000000081openalex-snapshot
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
inferredcites →https://doi.org/10.1111/1346-8138.12991openalex-snapshot
Case of respiratory discomfort due to myositis after administration of nivolumab
inferredcites →https://doi.org/10.1126/science.1246886openalex-snapshot
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
inferredcites →https://doi.org/10.1136/annrheumdis-2011-200697openalex-snapshot
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy
inferredcites →https://doi.org/10.1136/annrheumdis-2016-209595openalex-snapshot
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
inferredcites →https://doi.org/10.1158/2326-6066.cir-15-0035openalex-snapshot
Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
inferredcites →https://doi.org/10.1158/2326-6066.cir-15-0186openalex-snapshot
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1186/s12916-015-0455-8openalex-snapshot
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
inferredcites →https://doi.org/10.1186/s40425-014-0041-1openalex-snapshot
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
inferredcites →https://doi.org/10.1186/s40425-015-0064-2openalex-snapshot
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
inferredcites →https://doi.org/10.1200/jco.2005.04.5716openalex-snapshot
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
inferredcites →https://doi.org/10.1200/jco.2009.26.7609openalex-snapshot
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
inferredcites →https://doi.org/10.1200/jco.2012.41.6750openalex-snapshot
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
inferredcites →https://doi.org/10.1200/jco.2012.47.5095openalex-snapshot
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
inferredcites →https://doi.org/10.1200/jco.2014.58.3708openalex-snapshot
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0160221openalex-snapshot
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
inferredcites →https://doi.org/10.14694/edbook_am.2015.35.76openalex-snapshot
Managing Immune Checkpoint-Blocking Antibody Side Effects
inferredcites →https://doi.org/10.2146/ajhp140768openalex-snapshot
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
inferredcites →https://doi.org/10.2214/ajr.10.6198openalex-snapshot
Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4854762openalex-extracted
Characterization of Immune Checkpoint Inhibitor-Associated Arthritis: Insights from the Two Global Pharmacovigilance Databases of FAERS and VigiBase
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.0032openalex-snapshot
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
inferred← citeshttps://doi.org/10.1002/9781119823766.ch50openalex-snapshot
Identification and Management of Immunotherapy‐Related Adverse Events in Oncology
inferred← citeshttps://doi.org/10.1002/9781119858430.ch18openalex-snapshot
Autoimmune Phenomena in Cancer Patients Treated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/9781119858430.ch22openalex-snapshot
Sjögren's Syndrome as a Proof of Concept of the Hyperstimulation Syndrome
inferred← citeshttps://doi.org/10.1002/acr.23467openalex-snapshot
Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
inferred← citeshttps://doi.org/10.1002/acr.23481openalex-snapshot
Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al
inferred← citeshttps://doi.org/10.1002/acr.25604openalex-snapshot
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis
inferred← citeshttps://doi.org/10.1002/acr.80099openalex-snapshot
The Clinical Framework of Onco‐Geri‐Rheumatology: Integrating Aging Biology, Cancer Immunotherapy, and Autoimmune Disease Care
inferred← citeshttps://doi.org/10.1002/acr2.1026openalex-snapshot
Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series
inferred← citeshttps://doi.org/10.1002/acr2.11787openalex-snapshot
Prevalence of Autoimmune Diseases in Patients Treated With Immune Checkpoint Inhibitors: An Epidemiological Study Using A Global Network of Health Care Organizations
inferred← citeshttps://doi.org/10.1002/acr2.70002openalex-snapshot
Chronicity of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno‐Oncology Database
inferred← citeshttps://doi.org/10.1002/acr2.90092openalex-snapshot
Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity
inferred← citeshttps://doi.org/10.1002/art.41064openalex-snapshot
Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?
inferred← citeshttps://doi.org/10.1002/art.41587openalex-snapshot
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
inferred← citeshttps://doi.org/10.1002/art.41949openalex-snapshot
Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer
inferred← citeshttps://doi.org/10.1002/art.42749openalex-snapshot
Programmed Death Ligand 1–Expressing Macrophages and Their Protective Role in the Joint During Arthritis
inferred← citeshttps://doi.org/10.1002/art.70149openalex-snapshot
Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data
inferred← citeshttps://doi.org/10.1002/cncr.33436openalex-snapshot
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana‐Farber Cancer Institute, 2011 to 2019
inferred← citeshttps://doi.org/10.1002/iub.2558openalex-snapshot
PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_16openalex-snapshot
Renal Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-030-44234-7_24openalex-snapshot
Rheumatic Syndromes Related to Malignant Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_4openalex-snapshot
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritis
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_5openalex-snapshot
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_6openalex-snapshot
Myositis
inferred← citeshttps://doi.org/10.1007/978-3-030-74028-3_7openalex-snapshot
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_16openalex-snapshot
Renal Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-031-33924-0_17openalex-snapshot
Toxic and Drug-Induced Myopathies
inferred← citeshttps://doi.org/10.1007/s00223-026-01489-8openalex-snapshot
Bone Adverse Events in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Comprehensive Review of the Literature from the Clinical Action Group of the European Calcified Tissue Society
inferred← citeshttps://doi.org/10.1007/s00259-022-05780-2openalex-snapshot
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
inferred← citeshttps://doi.org/10.1007/s00259-022-05788-8openalex-snapshot
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00261-020-02531-5openalex-snapshot
Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
inferred← citeshttps://doi.org/10.1007/s00393-020-00825-zopenalex-snapshot
Diagnostik und Management rheumatischer „immune-related adverse events“
inferred← citeshttps://doi.org/10.1007/s00393-022-01311-4openalex-snapshot
Rheumatologische Nebenwirkungen von Checkpointinhibitoren und deren Behandlung
inferred← citeshttps://doi.org/10.1007/s00393-025-01673-5openalex-snapshot
Update zur Behandlung immunvermittelter rheumatischer Nebenwirkungen unter Immuncheckpointinhibition
inferred← citeshttps://doi.org/10.1007/s00393-026-01878-2openalex-snapshot
Myositis unter Immuncheckpoint-Inhibitor-Therapie
inferred← citeshttps://doi.org/10.1007/s00520-020-05710-8openalex-snapshot
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors
inferred← citeshttps://doi.org/10.1007/s00520-024-08538-8openalex-snapshot
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study
inferred← citeshttps://doi.org/10.1007/s00520-026-10440-4openalex-snapshot
Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics
inferred← citeshttps://doi.org/10.1007/s00520-026-10945-yopenalex-snapshot
Diagnosis and management of immune checkpoint inhibitor–induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review
inferred← citeshttps://doi.org/10.1007/s10067-018-4035-0openalex-snapshot
Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment
inferred← citeshttps://doi.org/10.1007/s10067-019-04451-2openalex-snapshot
Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis
inferred← citeshttps://doi.org/10.1007/s10238-024-01317-zopenalex-snapshot
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort
inferred← citeshttps://doi.org/10.1007/s10549-021-06480-5openalex-snapshot
Immunotherapy toxicity: identification and management
inferred← citeshttps://doi.org/10.1007/s10555-021-09976-0openalex-snapshot
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
inferred← citeshttps://doi.org/10.1007/s11739-020-02295-2openalex-snapshot
Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach
inferred← citeshttps://doi.org/10.1007/s11864-018-0562-9openalex-snapshot
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
inferred← citeshttps://doi.org/10.1007/s11864-019-0647-0openalex-snapshot
Pain in Cancer Survivors: How to Manage
inferred← citeshttps://doi.org/10.1007/s11910-020-01038-2openalex-snapshot
Neurologic Toxicities of Cancer Immunotherapies: a Review
inferred← citeshttps://doi.org/10.1007/s11912-018-0718-6openalex-snapshot
Immune Checkpoint Inhibitor Toxicity
inferred← citeshttps://doi.org/10.1007/s12688-024-00814-zopenalex-snapshot
Behandlung einer GPA-ähnlichen Erkrankung bei metastasiertem Melanom
inferred← citeshttps://doi.org/10.1007/s15002-021-3328-xopenalex-snapshot
Diagnostik und Management rheumatischer "immune-related adverse events"
inferred← citeshttps://doi.org/10.1007/s15011-023-5981-7openalex-snapshot
Nebenwirkungen frühzeitig erkennen und erfolgreich managen
inferred← citeshttps://doi.org/10.1007/s40141-021-00323-6openalex-snapshot
Novel Cancer Therapeutics and Implications for Rehabilitation
inferred← citeshttps://doi.org/10.1007/s40141-024-00454-6openalex-snapshot
Evaluation and Management of Shoulder Dysfunction in Cancer Survivors
inferred← citeshttps://doi.org/10.1007/s40261-018-0735-0openalex-snapshot
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
inferred← citeshttps://doi.org/10.1007/s40265-021-01507-zopenalex-snapshot
Ocular Toxicity of Targeted Anticancer Agents
inferred← citeshttps://doi.org/10.1007/s40487-019-0096-8openalex-snapshot
A Review of Immune-Mediated Adverse Events in Melanoma
inferred← citeshttps://doi.org/10.1007/s40674-017-0075-xopenalex-snapshot
Idiopathic Inflammatory Myopathies and Malignancy
inferred← citeshttps://doi.org/10.1007/s40674-019-00131-zopenalex-snapshot
Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments
inferred← citeshttps://doi.org/10.1007/s40744-020-00246-zopenalex-snapshot
Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature
inferred← citeshttps://doi.org/10.1007/s40744-021-00359-zopenalex-snapshot
Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy
inferred← citeshttps://doi.org/10.1007/s40801-023-00399-7openalex-snapshot
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
inferred← citeshttps://doi.org/10.1016/b978-0-12-812102-3.00003-8openalex-snapshot
General Features of Autoimmune Disease
inferred← citeshttps://doi.org/10.1016/b978-0-12-818006-8.00001-3openalex-snapshot
Autoimmune diseases
inferred← citeshttps://doi.org/10.1016/b978-0-12-820239-5.00011-5openalex-snapshot
Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
inferred← citeshttps://doi.org/10.1016/b978-0-323-67241-2.00024-0openalex-snapshot
Rheumatological Toxicities of Immunotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-85661-4.00006-8openalex-snapshot
Cancer precision medicine: Focus on gastrointestinal cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-24742-2.00006-xopenalex-snapshot
Managing adverse effects of novel immunotherapies in pancreatic and colon cancers
inferred← citeshttps://doi.org/10.1016/b978-0-443-30050-9.00006-0openalex-snapshot
Treating pain resulting from cancer treatment
inferred← citeshttps://doi.org/10.1016/b978-0-7020-8165-1.00057-5openalex-snapshot
Inflammatory Muscle Diseases
inferred← citeshttps://doi.org/10.1016/bs.mcb.2025.02.015openalex-snapshot
Autoimmune arthritis: Transgenic mouse models and methods
inferred← citeshttps://doi.org/10.1016/j.abd.2026.501422openalex-snapshot
Immune checkpoint inhibitor-associated eosinophilic fasciitis: a systematic review of reported cases
inferred← citeshttps://doi.org/10.1016/j.acra.2022.03.007openalex-snapshot
Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review
inferred← citeshttps://doi.org/10.1016/j.annonc.2022.10.001openalex-snapshot
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.arcmed.2021.09.004openalex-snapshot
Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.autrev.2018.01.003openalex-snapshot
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.autrev.2018.01.010openalex-snapshot
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.autrev.2019.06.005openalex-snapshot
Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer
inferred← citeshttps://doi.org/10.1016/j.autrev.2020.102590openalex-snapshot
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
inferred← citeshttps://doi.org/10.1016/j.autrev.2020.102595openalex-snapshot
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
inferred← citeshttps://doi.org/10.1016/j.berh.2019.03.009openalex-snapshot
Checkpoint inhibitor-associated autoimmunity
inferred← citeshttps://doi.org/10.1016/j.berh.2019.101437openalex-snapshot
How to investigate: Suspected systemic rheumatic diseases in patients presenting with muscle complaints
inferred← citeshttps://doi.org/10.1016/j.berh.2022.101805openalex-snapshot
Treatment of rheumatic adverse events of cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.berh.2026.102147openalex-snapshot
The management of rheumatic immune related adverse events
inferred← citeshttps://doi.org/10.1016/j.berh.2026.102152openalex-snapshot
Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2025.123419openalex-snapshot
Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation
inferred← citeshttps://doi.org/10.1016/j.bjps.2025.02.012openalex-snapshot
Delineating upper limb longitudinal recovery after simple mastectomy, implant or autologous breast reconstruction using wearable activity monitors
inferred← citeshttps://doi.org/10.1016/j.bulcan.2021.01.016openalex-snapshot
Effets secondaires rhumatologiques immuno-induits par les inhibiteurs de points de contrôle de la réponse immunitaire
inferred← citeshttps://doi.org/10.1016/j.cell.2021.02.011openalex-snapshot
Understanding and treating the inflammatory adverse events of cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.01.021openalex-snapshot
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.clim.2020.108395openalex-snapshot
Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations
inferred← citeshttps://doi.org/10.1016/j.clim.2020.108497openalex-snapshot
Sicca syndrome following immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1016/j.clinme.2025.100496openalex-snapshot
Immune checkpoint inhibitor-induced inflammatory arthritis
inferred← citeshttps://doi.org/10.1016/j.cmrp.2020.05.004openalex-snapshot
Real-life experience with nivolumab monotherapy in patients with advanced lung cancer: Efficacy and immune-related adverse events at Jiangsu Cancer Hospital, Nanjing, China
inferred← citeshttps://doi.org/10.1016/j.cpet.2023.12.012openalex-snapshot
PET/Computed Tomography Transformation of Oncology
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103919openalex-snapshot
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review
inferred← citeshttps://doi.org/10.1016/j.ctrv.2017.05.003openalex-snapshot
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102189openalex-snapshot
Neurological complications of cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.11.003openalex-snapshot
Immune checkpoint inhibitors: a promising anticancer therapy
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.05.032openalex-snapshot
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
inferred← citeshttps://doi.org/10.1016/j.ejca.2024.114148openalex-snapshot
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease
inferred← citeshttps://doi.org/10.1016/j.ejro.2022.100434openalex-snapshot
Imaging features of toxicities associated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.hoc.2018.12.008openalex-snapshot
Immunotherapy Toxicity
inferred← citeshttps://doi.org/10.1016/j.humpath.2019.07.001openalex-snapshot
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma
inferred← citeshttps://doi.org/10.1016/j.imlet.2020.02.008openalex-snapshot
Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer
inferred← citeshttps://doi.org/10.1016/j.jaip.2026.02.027openalex-snapshot
A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions
inferred← citeshttps://doi.org/10.1016/j.jaut.2020.102546openalex-snapshot
Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer
inferred← citeshttps://doi.org/10.1016/j.jaut.2026.103616openalex-snapshot
Profiling immune check point inhibitors – Induced arthritis: A systematic review and pooled analyses of cohort studies
inferred← citeshttps://doi.org/10.1016/j.jbspin.2021.105168openalex-snapshot
Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival
inferred← citeshttps://doi.org/10.1016/j.jbspin.2022.105403openalex-snapshot
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jbspin.2022.105457openalex-snapshot
Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer
inferred← citeshttps://doi.org/10.1016/j.jbspin.2025.105938openalex-snapshot
Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review
inferred← citeshttps://doi.org/10.1016/j.jfma.2020.04.004openalex-snapshot
The PD-1/PD-L pathway in rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.jncc.2025.05.004openalex-snapshot
Neuromuscular complications associated with cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jocd.2026.101742openalex-snapshot
Opportunistic evaluation and follow-up of bone mineral density by CT for patients receiving immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.jpainsymman.2018.05.015openalex-snapshot
Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
inferred← citeshttps://doi.org/10.1016/j.jss.2022.08.040openalex-snapshot
A Review of Immune Checkpoint Blockade for the General Surgeon
inferred← citeshttps://doi.org/10.1016/j.lpm.2026.104340openalex-snapshot
Immune checkpoint inhibitor-induced joint involvement
inferred← citeshttps://doi.org/10.1016/j.mayocp.2017.03.016openalex-snapshot
Scleroderma Induced by Pembrolizumab: A Case Series
inferred← citeshttps://doi.org/10.1016/j.mcna.2020.09.009openalex-snapshot
Rheumatic Complications of Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.mcpro.2026.101633openalex-snapshot
Sugar-Coded Signals: Glycan-Based Biomarkers in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1016/j.medcle.2020.06.030openalex-snapshot
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
inferred← citeshttps://doi.org/10.1016/j.medcli.2020.06.057openalex-snapshot
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
inferred← citeshttps://doi.org/10.1016/j.neurol.2023.03.029openalex-snapshot
Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: Are we missing something?
inferred← citeshttps://doi.org/10.1016/j.rcreu.2020.06.002openalex-snapshot
Diagnóstico diferencial dentro del espectro del síndrome de Sjögren
inferred← citeshttps://doi.org/10.1016/j.rdc.2020.04.003openalex-snapshot
Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity
inferred← citeshttps://doi.org/10.1016/j.rdc.2020.05.002openalex-snapshot
Overview of the Associations Between Cancer and Rheumatic Disease
inferred← citeshttps://doi.org/10.1016/j.rdc.2022.02.002openalex-snapshot
Rheumatic Complications of Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1016/j.rdc.2024.01.002openalex-snapshot
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
inferred← citeshttps://doi.org/10.1016/j.rdc.2024.02.002openalex-snapshot
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
inferred← citeshttps://doi.org/10.1016/j.rdc.2024.02.005openalex-snapshot
Imaging in Rheumatic Immune-related Adverse Events
inferred← citeshttps://doi.org/10.1016/j.reuma.2018.08.008openalex-snapshot
Inmunoterapia, cáncer y enfermedades reumatológicas: revisión de la literatura y serie de casos en un hospital universitario
inferred← citeshttps://doi.org/10.1016/j.reuma.2019.03.004openalex-snapshot
Inmunoterapia, cáncer y enfermedades reumatológicas
inferred← citeshttps://doi.org/10.1016/j.reuma.2022.09.004openalex-snapshot
Eventos adversos reumatológicos secundarios al uso de inhibidores de punto de control inmunitario
inferred← citeshttps://doi.org/10.1016/j.reumae.2018.08.011openalex-snapshot
Immunotherapy, cancer and rheumatological diseases: A review of the literature and a series of cases in a university hospital
inferred← citeshttps://doi.org/10.1016/j.reumae.2019.03.002openalex-snapshot
Immunotherapy, cancer and rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.reumae.2023.03.001openalex-snapshot
Rheumatological adverse events secondary to immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.revmed.2021.01.002openalex-snapshot
Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est
inferred← citeshttps://doi.org/10.1016/j.rhum.2021.10.564openalex-snapshot
Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale
inferred← citeshttps://doi.org/10.1016/j.rhum.2022.07.020openalex-snapshot
Effets indésirables rhumatologiques des inhibiteurs de point de contrôle PD-(L)1 dans le cancer du poumon : revue systématique et méta-analyse
inferred← citeshttps://doi.org/10.1016/j.rhum.2025.12.021openalex-snapshot
Manifestations rhumatologiques des traitements du cancer et leur prise en charge
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2018.02.011openalex-snapshot
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2018.10.012openalex-snapshot
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2019.04.002openalex-snapshot
Immune-mediated necrotising myopathy: A critical review of current concepts
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2022.152110openalex-snapshot
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2024.152573openalex-snapshot
Musculoskeletal Ultrasound Characteristics of Checkpoint Inhibitor-Associated Inflammatory Arthritis
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2024.152582openalex-snapshot
Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1?
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2025.152773openalex-snapshot
Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis
inferred← citeshttps://doi.org/10.1016/j.semarthrit.2026.153042openalex-snapshot
Immune checkpoint inhibitor-associated eosinophilic fasciitis: A FAERS pharmacovigilance analysis of a rare rheumatic immune-related adverse event
inferred← citeshttps://doi.org/10.1016/j.seminoncol.2025.152345openalex-snapshot
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment
inferred← citeshttps://doi.org/10.1016/j.smim.2021.101473openalex-snapshot
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
inferred← citeshttps://doi.org/10.1016/j.soc.2025.10.010openalex-snapshot
Contemporary Management of Immune Checkpoint Inhibitor-related Adverse Events
inferred← citeshttps://doi.org/10.1016/j.soncn.2019.08.005openalex-snapshot
Acute and Long-term Adverse Events Associated With Checkpoint Blockade
inferred← citeshttps://doi.org/10.1016/j.survophthal.2021.01.001openalex-snapshot
Ocular side effects of checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.yaoo.2025.03.002openalex-snapshot
Anterior Segment Manifestations and Complications of Systemic Drug Therapy
inferred← citeshttps://doi.org/10.1016/j.ygyno.2022.05.003openalex-snapshot
Immunotherapy toxicities: An SGO clinical practice statement
inferred← citeshttps://doi.org/10.1016/s1169-8330(17)30327-7openalex-snapshot
Complications rhumatologiques de l’immunothérapie anticancéreuse
inferred← citeshttps://doi.org/10.1016/s2665-9913(23)00064-4openalex-snapshot
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study
inferred← citeshttps://doi.org/10.1016/s2665-9913(25)00077-3openalex-snapshot
What can imaging teach us about immune checkpoint inhibitor-induced arthritis?
inferred← citeshttps://doi.org/10.1024/1661-8157/a003979openalex-snapshot
Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic Toxicities
inferred← citeshttps://doi.org/10.1038/s41379-018-0164-xopenalex-snapshot
A pattern-based approach to the interpretation of skeletal muscle biopsies
inferred← citeshttps://doi.org/10.1038/s41379-020-00682-wopenalex-snapshot
MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1038/s41392-020-00264-xopenalex-snapshot
Targeted therapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41392-025-02241-8openalex-snapshot
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
inferred← citeshttps://doi.org/10.1038/s41423-022-00947-1openalex-snapshot
Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy
inferred← citeshttps://doi.org/10.1038/s41571-019-0218-0openalex-snapshot
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
inferred← citeshttps://doi.org/10.1038/s41571-020-0352-8openalex-snapshot
Moving towards personalized treatments of immune-related adverse events
inferred← citeshttps://doi.org/10.1038/s41571-025-01029-7openalex-snapshot
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
inferred← citeshttps://doi.org/10.1038/s41572-020-0160-6openalex-snapshot
Immune-related adverse events of checkpoint inhibitors
inferred← citeshttps://doi.org/10.1038/s41584-018-0074-9openalex-snapshot
Rheumatic immune-related adverse events from cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41598-021-88307-3openalex-snapshot
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1038/s41598-026-43606-5openalex-snapshot
Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2023.09.002openalex-snapshot
Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2022.10.002openalex-snapshot
Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity
inferred← citeshttps://doi.org/10.1055/a-0992-3717openalex-snapshot
Immunologische Nebenwirkungen von Checkpoint-Inhibitoren
inferred← citeshttps://doi.org/10.1055/a-1209-0659openalex-snapshot
Nebenwirkungen immunonkologischer Therapien
inferred← citeshttps://doi.org/10.1055/s-0041-1733788openalex-snapshot
Neurologic Complications in Patients with Cancer
inferred← citeshttps://doi.org/10.1055/s-0045-1814174openalex-snapshot
Rheumatic Immune-Related Adverse Events in Patients with Metastatic Melanoma: Insights for Treatment from a Single Cancer Center
inferred← citeshttps://doi.org/10.1080/03009742.2022.2053301openalex-snapshot
Sacroiliitis as an immune-related adverse event of pembrolizumb treatment for melanoma
inferred← citeshttps://doi.org/10.1080/08923973.2025.2542134openalex-snapshot
Implications of glucocorticoid-induced co-inhibitory molecule expression on combined glucocorticoid and immune checkpoint inhibitor therapy
inferred← citeshttps://doi.org/10.1080/1120009x.2025.2540173openalex-snapshot
A case of ICIs-associated arthritis caused by Toripalimab initially presenting as oedema in both lower limbs
inferred← citeshttps://doi.org/10.1080/14397595.2018.1532559openalex-snapshot
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy
inferred← citeshttps://doi.org/10.1080/14737140.2019.1562342openalex-snapshot
Management of immune-related adverse events resulting from immune checkpoint blockade
inferred← citeshttps://doi.org/10.1080/14740338.2017.1313228openalex-snapshot
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1080/14740338.2020.1757068openalex-snapshot
An update on the safety of nivolumab for the treatment of advanced melanoma
inferred← citeshttps://doi.org/10.1080/14740338.2024.2363471openalex-snapshot
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach
inferred← citeshttps://doi.org/10.1080/14740338.2026.2719047openalex-snapshot
Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/15265161.2018.1444823openalex-snapshot
Ethical Ruminations of a Rheumatologist: Autoimmunity Is an Important Consideration for Immunotherapy Trials
inferred← citeshttps://doi.org/10.1080/1744666x.2020.1804362openalex-snapshot
Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management
inferred← citeshttps://doi.org/10.1080/1744666x.2024.2370327openalex-snapshot
Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management
inferred← citeshttps://doi.org/10.1080/1750743x.2024.2436838openalex-snapshot
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/1750743x.2025.2501519openalex-snapshot
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/17843286.2019.1646516openalex-snapshot
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1080/2162402x.2023.2261264openalex-snapshot
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
inferred← citeshttps://doi.org/10.1093/immadv/ltab014openalex-snapshot
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1093/jbmr/zjaf009openalex-snapshot
Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning–assisted opportunistic quantitative computed tomography
inferred← citeshttps://doi.org/10.1093/med/9780198821328.003.0050openalex-snapshot
Management issues in chronic pain following cancer therapy
inferred← citeshttps://doi.org/10.1093/mrcr/rxae029openalex-snapshot
Calcium pyrophosphate crystal arthritis associated with immune checkpoint inhibitor successfully treated with intra-articular glucocorticoid: A case report
inferred← citeshttps://doi.org/10.1093/oncolo/oyac252openalex-snapshot
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
showing the first 200 of 400 · page through all 400
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.